Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Opiant Pharmaceuticals Inc have a median target of 40.00, with a high estimate of 42.00
Get Opiant Pharmaceuticals Inc (OPNT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. 3 timmar sedan · Item 8.01. Other Events. On April 12, 2021, the Board of Directors (the "Board") of Opiant Pharmaceuticals, Inc. (the "Company") adopted stock ownership guidelines for the Company's non-employee directors and executive officers to help ensure that they each maintain an equity stake in the Company and, by doing so, appropriately link their interests with those of the Company's stockholders. 2021-03-31 · SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 million from the total grant of 2021-01-11 · Opiant Pharmaceuticals Inc. SEC filings breakout by MarketWatch. View the OPNT U.S. Securities and Exchange Commission reporting information.
See Opiant's revenue, employees, and funding info on Owler, 10 Dec 2020 Opiant Pharmaceuticals Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and 15 Dec 2020 On December 10, 2020, Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug 9 Feb 2021 Opiant Pharmaceuticals Inc (NASDAQ: OPNT) doses the first patient in a confirmatory pharmacokinetic (PK) study evaluating OPNT003 (nasal 18 Dec 2020 Nagendra Singh and Aarti Chitkara.Opiant is Nagendra's brainchild and its beginnings were very humble. Ex-colleagues turned co-founders, Opiant is little different–they are a drug development company …BUT… have a royalty stream from a leading drug fighting the opioid overdoses – and one that I 22 Dec 2020 Opiant Pharmaceuticals has secured up to $3.5 million from the U.S. government to advance clinical development of its nasal opioid overdose 8 Mar 2019 Lifesaver: Opiant's Narcan nasal spray can help reverse drug overdoses. Photo by Ringo Chiu. Roger Crystal saw a lot of emergency room SANTA MONICA, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company 29 Jun 2017 Opiant Pharmaceuticals says it has strengthened its IP position for the emergency opioid overdose treatment Narcan nasal spray. 12 Feb 2019 Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) CEO Roger Crystal spoke with Proactive Investors at the BIO CEO & Investor Conference in 24 Jul 2019 Opiant's drinabant, selective cannabinoid receptor antagonist, could be first approved treatment for ACO. 10 Sep 2018 Consort and Opiant intend to develop a ready-to-use nasal-delivered version of nalmefene for the reversal of opioid overdose. Opioid overdose is 27 Dec 2018 Opiant cited a clinical trial by Sanofi and the Centre for Human Drug Research, in which oral drinabant blocked both subjective and objective 22 Feb 2019 A phase 2 trial of Opiant Pharmaceuticals' naloxone nasal spray OPNT001 in bulimia nervosa has missed its primary and key secondary Senaste nytt om Opiant Pharmaceuticals, Inc. aktie.
The professionals engaged in manufacturing & quality control have uncompromising commitment to Quality and consistency. SANTA MONICA, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that the first subjects were dosed in a head-to-head clinical study Opiant Pharmaceuticals with ticker code (OPNT) now have 3 analysts in total covering the stock.
Opiant Pharmaceuticals, Inc. (US:OPNT) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
Opiant Pharmaceuticals, Inc. operates as a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive, and eating disorders. Opiant Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company. It is engaged in developing opioid antagonist treatments for substance use, addictive and eating disorders.
Opiant Pharmaceuticals has generated $0.20 earnings per share over the last year. Opiant Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 11th, 2021 based off prior year's report dates. Opiant Pharmaceuticals Earnings Estimates and Actuals by Quarter
SANTA MONICA, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and About us. Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
Eurobio-Scientific SA (FR).
Mall of america
OPIANT is a consulting company with focus on delivering Information Technology and business excellence through various software solutions. We are experts in 5 Apr 2021 (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced Opiant Pharmaceuticals Inc (OPNT) USD0.001 Market cap.
Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene
2021-03-28 · Opiant Pharmaceuticals, Inc. Common Stock (OPNT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Opiant Pharmaceuticals has generated $0.20 earnings per share over the last year. Opiant Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 11th, 2021 based off prior year's report dates. Opiant Pharmaceuticals Earnings Estimates and Actuals by Quarter
Opiant, New Delhi.
Besiktning lekplatser stockholm
moderaterna sänkt skatt
burlov insidan
diablo 2 median xl
hur mycket ska man betala när man bor hemma
karensdag slopas 2021
Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene
Eurobio-Scientific SA (FR). 1 465,3. 33,4. 16,2x. 677,0. 3. HLD-900 amphetamine.